FDA Grants Ibrutinib/Rituximab Priority Review for Waldenstrom Macroglobulinemia
Pharma & biotech2018-06-25
10 Views
The FDA has granted a priority review to a supplemental new drug application ibrutinib for use in combination with rituximab as a treatment option across all lines of therapy for patients with Waldenström macroglobulinemia.
Source: OncLive
The news, reports, views and opinions of authors (or source) expressed are their own and do not necessarily represent the views of CRWE World.
Leading European Football Clubs Announce Participation in New Super League Competition
